The translocation (8;21)(q22;q22) is observed in approximately 12-15% of patients with acute myeloid leukaemia (AML), making it one of the most frequently observed translocations in AML. 1 The translocation involves DNA rearrangement of the RUNX1 (aka. AML1, core binding factor (CBFa)) gene on chromosome 21 with the RUNX1T1 (aka. ETO) gene on chromosome 8. This abnormality leads to the expression of the RUNX1-RUNX1T1 (aka. AML1-ETO) fusion gene, which promotes self-renewal of haematopoietic cells and also inhibits TAP1  TAP2  ABCB1  ABCB6  ABCB7   TAP1  TAP2  ABCB1  ABCB6  ABCB7  TAP1  TAP2  ABCB1  ABCB6  ABCB7   TAP1  TAP2  ABCB1  ABCB6 For caption see page 1884.
Letters to the Editor their subsequent differentiation. 2 Leukaemias expressing this abnormality are generally associated with a good prognosis in terms of complete remission, relapse risk and overall survival compared with other subtypes and tend to respond favourably to treatment particularly with high-dose cytarabine and an anthracycline. 3 It is currently not known why patients expressing the t(8;21) have a good prognosis. The chemosensitivity of patients with AML has previously been suggested to be associated with multi-drug resistance (MDR) gene expression. [4] [5] [6] The MDR-1 gene encodes P-glycoprotein, a cell membrane drug efflux pump. It would be envisaged that patients who are considered to have a good prognosis (such as t(8;21)) would not overexpress MDR-1 (as demonstrated by Lutterbach et al. 4 ), otherwise it is likely those individuals would show chemoresistance and have a more adverse prognoses. Surprisingly, previous studies have found positive correlations Effect of chemotherapeutic drugs on the growth of human progenitor cells expressing RUNX1-RUNX1T1. Human CD34 þ cells transduced with RUNX1-RUNX1T1 were assayed 3 days after retroviral transduction (in comparison with matched cultures expressing GFP alone). The numbers of GFP þ PI À cells were scored by a calibrated flow cytometric assay (as described previously) 2 after 2 days in culture treated with increasing doses of (a) Daunorubicin, Dau, (b) Cytarabine, Cyt, (c) Fludarabine, flu, (d) Idarubicin, Ida, (e) Etoposide, Eto or (f) combined drug treatment (using concentrations of drug that inhibited growth by 50%). Data indicate mean71 s.d. of a minimum of three independent replicate analyses.
Letters to the Editor between the t(8;21) karyotype and MDR-1 gene expression, 5, 6 suggesting that this transcription factor fusion gene may promote the expression of MDR-1. We therefore tested this hypothesis directly by expressing the RUNX1-RUNX1T1 fusion as a single abnormality in human haematopoietic cell subsets and performed Affymetrix microarray analysis (as described previously) 2, 7 to determine whether this fusion had any effect on the transcription of MDR genes. Using this approach, we generated independent replicate sets of data from control and RUNX1-RUNX1T1-matched CD34 þ cultures as well as matched sets constituting granulocytic (CD14 lo , CD36 lo , CD15 hi ) and monocytic (CD14 hi ) unilineage populations (isolated from day 6 cultures by immunomagnetic sorting). cRNA was prepared from each sample and hybridized to Affymetrix human 133A oligonucleotide arrays, which allowed the simultaneous analysis of six MDR family gene members. In each of these populations, the expression of MDR genes was not significantly different from controls (Figure 1a-c) . In addition, using our cohort of FrenchAmerican-British (FAB)-M2 patients, there was little difference in MDR gene expression between those individuals with a t(8;21) and those without this abnormality (Figure 1d ). We could therefore find no evidence that RUNX1-RUNX1T1 expression directly influences MDR gene expression as a single abnormality or in t(8;21) patients. One alternative explanation for the aforementioned observations in AML patients is that other coexisting abnormalities may be influencing the expression of MDR, as suggested by Schaich et al. 6 We next addressed the issue of whether the t(8;21) abnormality directly influences the susceptibility to chemotherapeutic agents. We therefore assessed the sensitivity of normal human cells (expressing RUNX1-RUNX1T1 as a single abnormality) to a number of drugs commonly used to treat AML (Daunorubicin, Cytarabine, Fludarabine, Idarubicin or Etoposide) in comparison with matched controls. Remarkably, none of these agents differentially affected the growth of RUNX1-RUNX1T1-transduced cells (Figure 2a-e) . As treatment of AML commonly involves multiple drugs, we also determined the effect of combining two or more of these chemotherapeutic agents (using drug concentrations that resulted in 50% reduction in cell growth as a single agent). Again, we observed little difference in the in vitro growth response of RUNX1-RUNX1T1-expressing cells compared to controls (Figure 2f) .
Taken together, these data suggest that expression of RUNX1-RUNX1T1 itself has no effect on the intrinsic susceptibility to cytotoxic chemicals. This raises the alternative hypothesis that RUNX1-RUNX1T1 moderates the influence of secondary abnormalities, which are required for RUNX1-RUNX1T1-expressing cells to undergo leukaemic transformation. 8 For example, it is known that RUNX1-RUNX1T1 specifically upregulates the expression of g-catenin in RUNX1-RUNX1T1-expressing cells and t(8;21) patients, 7,9 a protein that acts as a tumour suppressor gene in other contexts.
